COMP <GO>
WAT vs JNJ // REVENUE GROWTH (YOY)
Waters Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: WAT 4
— JNJ 10
▲ REVENUE GROWTH (YOY) LEADER: WAT
LAST: $462.72 (-3.61%) • MKT CAP: $47.17B
revenue-growth
7.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WAT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WAT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.30% | 67.90% | -8.60 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.80% | 25.50% | -8.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 51.5x | 18.5x | +33.00 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.08% | 2.97% | -1.89 | JNJ | /fcf-yield <GO> |
| Operating Margin | 25.40% | 34.70% | -9.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 28.50% | -8.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 7.00% | 6.00% | +1.00 | WAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.49 | 5.59 | +9.90 | WAT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | WAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.20% | -0.20 | WAT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.9 | 60.4 | -0.47 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.08 | -0.06 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 68.3x | 23.0x | +45.30 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $47.17B | $662.49B | -$615.33B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WAT REV | JNJ REV | WAT GROSS % | JNJ GROSS % | WAT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.17B | $94.19B | 59.3% | 67.9% | $510.1M | $19.70B |
| FY 2024 | $2.96B | $88.82B | 59.4% | 69.1% | $629.0M | $19.84B |
| FY 2023 | $2.96B | $85.16B | 44.0% | 44.0% | $469.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WAT // BETA 1.02
JNJ // BETA 1.08